Enoxaparin Sodium Injection, USP 100 mg/mL Single Dose Syringes with Automatic Safety Device For ...
FDA Drug Recall #D-0261-2021 — Class I — February 2, 2021
Recall Summary
| Recall Number | D-0261-2021 |
| Classification | Class I — Serious risk |
| Date Initiated | February 2, 2021 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Apotex Corp. |
| Location | Weston, FL |
| Product Type | Drugs |
| Quantity | 6670 cartons |
Product Description
Enoxaparin Sodium Injection, USP 100 mg/mL Single Dose Syringes with Automatic Safety Device For Subcutaneous Injection 10 x 1 mL Single Dose Syringes Rx Only, Manufactured by: Gland Pharma Ltd. Hyderabad, India Manufactured for: Apotex Corp. Weston, FL 33326 NDC 60505-0795-4 UPC 360505079544 (carton) NDC 60505-0795-1 UPC (01)10360505079510 (label)
Reason for Recall
Labeling; Label Mixup; syringe barrels may containing markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength)
Distribution Pattern
Nationwide
Lot / Code Information
Batch: CS008 Exp. 04/2022
Other Recalls from Apotex Corp.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0407-2026 | Class II | Brimonidine Tartrate/Timolol Maleate Ophthalmic... | Mar 5, 2026 |
| D-0676-2025 | Class II | Brimonidine Tartrate/Timolol Maleate Ophthalmic... | Sep 5, 2025 |
| D-0677-2025 | Class II | Ketorolac Tromethamine Ophthalmic Solution, 0.5... | Sep 5, 2025 |
| D-0457-2025 | Class II | Lacosamide Oral Solution, USP, 10 mg/mL, 200 mL... | May 28, 2025 |
| D-0494-2025 | Class II | Ketorolac Tromethamine Ophthalmic Solution, 0.5... | May 28, 2025 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.